Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.

Liu Y, Hong Z, Tan G, Dong X, Yang G, Zhao L, Chen X, Zhu Z, Lou Z, Qian B, Zhang G, Chai Y.

Int J Cancer. 2014 Aug 1;135(3):658-68. doi: 10.1002/ijc.28706. Epub 2014 Jan 17.

2.

LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.

Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Ressom HW.

J Proteome Res. 2012 Dec 7;11(12):5914-23. doi: 10.1021/pr300673x. Epub 2012 Nov 1.

3.

Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.

Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L.

J Proteome Res. 2012 Feb 3;11(2):1217-27. doi: 10.1021/pr2009252. Epub 2012 Jan 18.

PMID:
22200553
4.

Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W.

Mol Cell Proteomics. 2011 Jul;10(7):M110.004945. doi: 10.1074/mcp.M110.004945. Epub 2011 Apr 25. Erratum in: Mol Cell Proteomics. 2011 Nov;10(11). doi:10.1074/mcp.A110.004945.

5.

Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.

Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.

J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.

PMID:
18823443
6.

Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.

Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R.

Liver Int. 2014 Oct;34(9):1428-44. doi: 10.1111/liv.12541. Epub 2014 Apr 28.

7.

Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.

Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, Zhao X, Wang W, Lu X, Xu Z, Wang H, Xu G.

Mol Cell Proteomics. 2012 Feb;11(2):M111.010694. doi: 10.1074/mcp.M111.010694. Epub 2011 Nov 14.

8.

Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.

Bowers J, Hughes E, Skill N, Maluccio M, Raftery D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 1;966:154-62. doi: 10.1016/j.jchromb.2014.02.043. Epub 2014 Mar 2.

9.

Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.

Passos-Castilho AM, Carvalho VM, Cardozo KH, Kikuchi L, Chagas AL, Gomes-GouvĂȘa MS, Malta F, de Seixas-Santos Nastri AC, Pinho JR, Carrilho FJ, Granato CF.

BMC Cancer. 2015 Dec 18;15:985. doi: 10.1186/s12885-015-1995-1.

10.

Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma.

Lu Y, Li N, Gao L, Xu YJ, Huang C, Yu K, Ling Q, Cheng Q, Chen S, Zhu M, Fang J, Chen M, Ong CN.

Cancer Res. 2016 May 15;76(10):2912-20. doi: 10.1158/0008-5472.CAN-15-3199. Epub 2016 Mar 14.

11.

Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.

Passos-Castilho AM, Lo Turco E, Ferraz ML, Matos C, Silva I, Parise E, Pilau E, Gozzo F, Granato C.

J Gastrointestin Liver Dis. 2015 Mar;24(1):43-9. doi: 10.15403/jgld.2014.1121.pas.

12.

Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.

Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K.

Anal Chim Acta. 2012 Sep 19;743:90-100. doi: 10.1016/j.aca.2012.07.013. Epub 2012 Jul 20.

13.

Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.

Gao R, Cheng J, Fan C, Shi X, Cao Y, Sun B, Ding H, Hu C, Dong F, Yan X.

Sci Rep. 2015 Dec 10;5:18175. doi: 10.1038/srep18175.

14.

Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma.

Jiang C, Zhang Y, Yu HF, Yu XT, Zhou SJ, Tan YF.

Tumour Biol. 2012 Dec;33(6):2167-72. doi: 10.1007/s13277-012-0477-1. Epub 2012 Sep 1.

PMID:
22941466
15.

Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.

Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT, Luk JM.

Ann Surg Oncol. 2010 Sep;17(9):2518-25. doi: 10.1245/s10434-010-1038-8. Epub 2010 Mar 31.

16.

Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis.

Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D.

Cancer Sci. 2009 Apr;100(4):782-5.

PMID:
19469021
17.

Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.

Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P.

J Gastroenterol Hepatol. 2010 Jan;25(1):129-37. doi: 10.1111/j.1440-1746.2009.05988.x. Epub 2009 Sep 27.

PMID:
19793164
18.

Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.

Mustafa MG, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, Denner L, Elferink C.

Mol Cell Proteomics. 2013 Dec;12(12):3640-52. doi: 10.1074/mcp.M113.031252. Epub 2013 Sep 5.

19.

Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.

Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A.

Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1222-9. doi: 10.1158/1055-9965.EPI-10-1047. Epub 2011 Apr 5.

20.

Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS.

Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, Liu Y.

J Cancer Res Clin Oncol. 2010 Aug;136(8):1151-9. doi: 10.1007/s00432-010-0762-6. Epub 2010 Feb 4.

PMID:
20130913

Supplemental Content

Support Center